UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2123-10
Program Prior Authorization/Medical Necessity
Medication Afstyla® (antihemophilic factor [recombinant], single chain)
P&T Approval Date 3/2017, 3/2018, 3/2019, 3/2020, 9/2020, 9/2021, 9/2022, 9/2023, 3/2024,
3/2025
Effective Date 6/1/2025
1. Background
Afstyla (antihemophilic factor [recombinant], single chain) is a recombinant antihemophilic
factor indicated in adults and children with hemophilia A (congenital Factor VIII deficiency) for:
On-demand treatment and control of bleeding episodes
o
Routine prophylaxis to reduce the frequency of bleeding episodes
o
Perioperative management of bleeding
o
Afstyla is not indicated for the treatment of von Willebrand disease.
2. Coverage Criteriaa:
A. Initial Authorization:
1. Afstyla will be initially approved based on the following criteria:
a. All of the following:
(1) Diagnosis of hemophilia A
-AND-
(2) Patient is not a suitable candidate for treatment with shorter acting half-life Factor
VIII (recombinant) products [Advate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, or
Recombinate] as attested by the prescriber
-AND-
(3) One of the following:
(a) Patient is not to receive routine infusions more frequently than 3 times per week
-OR-
(b) Both of the following:
1. Patient is less than 12 years of age
© 2025 UnitedHealthcare Services, Inc.
1
-AND-
2. Pharmacokinetic (PK) testing results suggest that more frequent than 3 times
per week dosing is required
Authorization of therapy will be issued for 12 months.
B. Reauthorization
1. Afstyla will be approved based on all of the following criteria:
a. Documentation of positive clinical response to Afstyla therapy.
-AND-
b. One of the following:
(1) Patient is not to receive routine infusions more frequently than 3 times per week
-OR-
(2) Both of the following:
(a) Patient is less than 12 years of age
-AND-
(b) PK testing results suggest that more frequent than 3 times per week dosing is
required
Authorization of therapy will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
4. References:
1. Afstyla® [package insert]. Kankakee, IL: CSL Behring, LLC., June 2023.
2. Malec L, Shapiro AD. Hemophilia A and B: Routine management including prophylaxis. In:
UpToDate, Waltham, MA, 2025.
3. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and
Other Bleeding Disorders. MASAC Document #290, October 2, 2024.
© 2025 UnitedHealthcare Services, Inc.
2
Program Prior Authorization/Medical Necessity - Afstyla
Change Control
3/2017 New program.
3/2018 Annual review with no changes to coverage criteria.
3/2019 Annual review with no changes to coverage criteria. Updated reference.
3/2020 Annual review with no changes to coverage criteria.
9/2020 Updated preferred standard half-life recombinant products. Updated
references.
9/2021 Annual review with no changes to coverage criteria. Updated reference.
9/2022 Annual review. Added text “pharmacokinetic” to clarify abbreviation “PK”
with no changes to clinical intent. Updated background per prescribing
information and updated references.
9/2023 Annual review. Modified physician attestation to prescriber attestation.
Updated references.
3/2024 Annual review with no changes to coverage criteria.
3/2025 Annual review with no changes to coverage criteria. Updated references.
© 2025 UnitedHealthcare Services, Inc.
3